Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (8)	8/27/2002 3:22:48 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

GMZO Is up 14.97% on volume of 116K after it said that it has effectively tested cancer-specific T-cells against nearly 50 million synthetic protein fragments, or peptides, to determine which ones respond most notably and can be targeted for clinical vaccine development. They are developing SPHERE, a method of identifying proteins associated with cancer tumors that could allow for the creation of cancer vaccines. They are planning to launch their first clinical trial next year using several of these SPHERE peptides in melanoma. siliconinvestor.com siliconinvestor.com Bernard